Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · IEX Real-Time Price · USD
2.285
-0.065 (-2.77%)
Jul 22, 2024, 9:54 AM EDT - Market open
Cocrystal Pharma Employees
Cocrystal Pharma had 12 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,395,917
Market Cap
23.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Trinity Biotech | 380 |
Biora Therapeutics | 58 |
HCW Biologics | 45 |
Femasys | 34 |
CytoMed Therapeutics | 28 |
Unity Biotechnology | 19 |
BioVie | 18 |
NeuroOne Medical Technologies | 16 |
COCP News
- 2 months ago - Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 2 months ago - Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - Accesswire
- 8 months ago - Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A - GlobeNewsWire
- 8 months ago - Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast - GlobeNewsWire
- 8 months ago - Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 - GlobeNewsWire